(PRWEB) December 20, 2001
BRUSSELS, Belgium.ÂDecember 20, 2001--Euroscreen s.a. these days announced an exclusive license agreement with The University of Virginia Patent
Foundation (UVAPF) for psychosine (TDAG8) receptor technologies that was developed at the University of Virginia.
Several lysophospholipids are thought to act as additional-cellular mediators in cell signaling by way of G protein coupled receptors (GPCRs). Earlier this year, researchers at the University of Virginia deorphanized a new G protein-coupled receptor, named TDAG8 (T cell Death Associated Gene protein# 8 GPR 65), which is a receptor for the glycosphingolipid, psychosine. In the lipid storage disorder known as Krabbe's illness psychosine accumulates to inordinately high levels. KrabbeÂs illness is a genetic disorder characterized by multinuclear, globoid cells in the white matter of the brain and global de-myelination of central and peripheral neurons. It is plausible for that reason that psychosine activation of TDAG8 in brain microglia might be the molecular basis underlying the patho-physiology of Krabbe's disease, a illness in which there is a lack of the production of galactosylceramidase, the enzyme which catalyzes the cleavage of psychosine to galactose and sphingosine. This invention need to significantly facilitate the discovery and characterization of psychosine receptor agonists and antagonists, which might be of therapeutic value in a variety of diseases which involve this receptor and its natural ligand. Euroscreen has a study team seeking to identify such drug candidates, but is also willing to sublicense to significant investigation partners to assist in this effort.
Euroscreen integrates its world class G protein-coupled receptor (GPCR)
study capabilities with its patented AequoScreen cellular assay
technology to provide new, innovative solutions to GPCR drug discovery. With its corporate partners as well as by means of its own internal development efforts Euroscreen continues to uncover crucial new drug leads and to boost its patent portfolio with the pivotal patent applications for the utility of CCR5 for HIV being an outstanding example. The Organization has corporate partnerships with Solvay, Merck & Co., Syngenta, Galapagos, Sosei and Nanosyn as well as licensing agreements with the Brussels University, the University of Virginia Patent Foundation and the University of Georgia Investigation Foundation. The Business applies its GPCR and ligand technology approaches to deorphanize certain targets and believes that its unique technique increases the chances of successfully creating commercial goods. Far more data about Euroscreen's goods and services can be discovered at http://www.euroscreen.be.
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.